CBD promotes oxaliplatin-mediated autophagy via NOS3 -mediated mitochondrial dysfunction, implying that NOS3 is a viable therapeutic target for overcoming oxaliplatin resistance and that CBD could be a novel treatment option for CRC (Jeong et al. 2019). This evidence concerns the gene NOS3 and colorectal carcinoma.